203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patchPRESCRIBING INFORMATION
Norelgestromin and ethinyl estradiol.
Please refer to Summary of Product Characteristics (SmPC) before prescribing.
Female contraception. Safety/efficacy established in women aged 18-45 years.
DOSAGE & ADMINISTRATION:
Adults: Transdermal use. One patch for 7 days, for 3 weeks followed by 1 week patch free. No data in women >45 years of age. Contraceptive efficacy in women ≥ 90kg may be reduced
Children: Not recommended < 18 years of age
Renal impairment: not studied but supervision required.
Hepatic impairment: Not studied – see contraindications.
Hypersensitivity. Presence or risk of venous or arterial thromboembolism (VTE/ATE), (refer to SmPC): Current VTE requiring anticoagulant therapy, history of deep vein thrombosis (DVT), or pulmonary embolism. Known hereditary or acquired risk of VTE or known thrombogenic mutations. Major surgery with prolonged immobilisation. History of myocardial infarction, angina pectoris. Presence of one serious risk factor for ATE: diabetes with vascular symptoms, severe hypertension, severe dyslipoproteinaemia. Cerebrovascular disease, current/history stroke, transient ischaemic attacks. Known hereditary or acquired predisposition for ATE. History of migraine with focal neurological symptoms. Known or suspected carcinoma breast, endometrium or other oestrogen-dependent neoplasia. Hepatic adenomas or carcinoma. Abnormal liver function related to acute or chronic hepatocellular disease. Undiagnosed abnormal genital bleeding. Drug combinations with paritaprevir/ritonavir, ombitasvir, and/or dasabuvir.
SPECIAL WARNINGS & PRECAUTIONS:
Exclude likelihood of pregnancy before starting treatment. Prior to initiation (and at regular intervals) assess personal and family medical history, measure blood pressure and perform physical examination. Discuss associated risk of VTE/ATE, known personal risk factors and symptoms of VTE and ATE. Increased risk of VTE in 6 week period of puerperium. Instruct to read leaflet carefully. Advise hormonal contraceptives do not protect against HIV infections or sexually transmitted disease. Discontinue: appearance of any contraindication; high blood pressure not responding to treatment; recurrence of cholestatic-related pruritus. Consider discontinuing: aggravation/new risk factors for VTE/ATE; acute/chronic liver function disturbances. As with all combined hormonal contraceptives: increased risk of cervical & breast cancer, worsening depression and risk of suicidal behaviour/suicide (women advised to contact physician in case of mood changes), epilepsy, Crohn’s disease, ulcerative colitis.
Following may occur or deteriorate: jaundice and/or pruritus related to cholestasis, gallbladder disease including cholecystitis and cholelithiasis, porphyria, SLE, haemolytic uraemic syndrome, Sydenham’s chorea, herpes gestationis, otosclerosis-related hearing loss, chloasma. Hepatic tumours reported rarely. Possible increased risk of pancreatitis with hypertriglyceridaemia (including family history). Observe diabetic women carefully. Irregular spotting or bleeding, especially in early treatment. Amenorrhoea/oligomenorrhoea after discontinuation.
Very common: headache, nausea, breast tenderness.
Common: (vulvo) vaginal fungal infection, vaginal candidiasis, mood, affect/anxiety disorders, migraine, dizziness, vomiting, diarrhoea, abdominal pain/distension, acne, rash, pruritus, skin reaction/irritation, muscle spasms, dysmenorrhoea, vaginal bleeding and menstrual disorders, uterine spasm, breast disorders, vaginal discharge, malaise, fatigue, application site reactions (erythema, irritation, pruritus, rash), weight increased.
Other side effects: hepatic neoplasm/adenoma, breast cancer, cervix carcinoma, uterine leiomyoma, fibroadenoma of breast, hypersensitivity, anaphylactic reaction, hypercholesterolaemia, hyperglycaemia/insulin resistance, cerebrovascular accident, cerebral haemorrhage, arterial thromboembolism, (acute) myocardial infarction, hypertension, hypertensive crisis, thrombosis (arterial/venous/pulmonary), venous thromboembolism, pulmonary embolism, hepatic lesion, jaundice cholestatic, cholestasis, angioedema, cervical dysplasia, lipid disorders.
Refer to SmPC for other side effects.
Contraindicated: drug combinations containing paritaprevir/ritonavir, ombitasvir, and/or dasabuvir. Contraceptive failure: As with other combined contraceptives may occur with hepatic enzymes inducers; including, but not limited to: antiepileptics, certain antivirals (HIV medication ritonavir, nevirapine, efavirenz) and antifungals, antibiotics (rifampicin), sedatives (barbiturates), bosentan, modafinil and St John’s Wort. Combinations of HIV protease inhibitors and non‑nucleoside reverse transcriptase inhibitors, including HCV inhibitors, can increase/decrease plasma concentrations of oestrogen/progestins. Etoricoxib. Evra affects plasma concentrations of lamotrigine (reduces) and ciclosporin (increases). Some endocrine, liver function and blood component tests may be affected. For further information read Evra SmPC and SmPC for co-prescribed medication(s).
Refer to SmPC for full details of interactions.
LEGAL CATEGORY: POM
PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER(S) & BASIC NHS COSTS
|MARKETING AUTHORISATION NUMBER(S)||BASIC NHS COSTS|
|Transdermal Patch||9 patches||
NI: EU 1/02/223/002
GB: PLGB 00232/0679
MARKETING AUTHORISATION HOLDER:
Northern Ireland: Janssen-Cilag International NV, Turnhoutseweg, 30, B-2340 Beerse, Belgium.
Great Britain: Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK.
Prescribing information last revised: March 2021